AzTrials
AzTrials

Chronic Lymphocytic LeukemiaPhase 3NCT07277231

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

A Phase 3 study testing Sonrotoclax, Zanubrutinib and Acalabrutinib in people with Chronic Lymphocytic Leukemia, run by BeOne Medicines at 115 sites in 17 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL). Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Chronic Lymphocytic Leukemia
What is being tested?
Sonrotoclax, Zanubrutinib and Acalabrutinib
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
500 participants
Where
115 sitesin 17 countries
Study dates
22 Jan 2026to Nov 2031
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment
  • Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2
  • Measurable disease by Computer Tomography/Magnetic Resonance Imaging
  • Adequate bone marrow and organ function

Who cannot join

  • Previous systemic treatment for CLL
  • Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation
  • Known central nervous system involvement
  • History of confirmed progressive multifocal leukoencephalopathy (PML)
  • Uncontrolled hypertension or clinically significant cardiovascular disease
  • Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Trial locations and contacts

115 sites in 17 countries. Contact the study team or a site near you to ask about taking part.

Study Director contact

8778285568

clinicaltrials@beonemed.com

115 sites in 17 countries

United States22 sites, 22 recruiting

  • Rocky Mountain Cancer Centers (Williams) Usor

    Aurora, Colorado, 80012-5405

    Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215-5418

    Recruiting

  • Atrium Health Levine Cancer Institute (Lci)

    Charlotte, North Carolina, 28204-2990

    Recruiting

  • Northwestern University

    Chicago, Illinois, 60611

    Recruiting

  • City of Hope National Medical Center

    Duarte, California, 91010-3012

    Recruiting

  • Duke University Medical Center

    Durham, North Carolina, 27705-3976

    Recruiting

  • Oncology Associates of Oregon Willamette Valley Cancer Center

    Eugene, Oregon, 97401

    Recruiting

  • Mayo Clinic Jacksonville

    Jacksonville, Florida, 32224-1865

    Recruiting

  • Mount Sinai Medical Center Braman Comprehensive Cancer Center

    Miami, Florida, 33140

    Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226-3522

    Recruiting

  • Ochsner Clinic Foundation

    New Orleans, Louisiana, 70121-2429

    Recruiting

  • Columbia University Medical Center

    New York, New York, 10032

    Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198

    Recruiting

  • Chao Family Comprehensive Cancer Center

    Orange, California, 92868-3201

    Recruiting

  • Stanford Cancer Institute

    Palo Alto, California, 94304-2205

    Recruiting

  • Upmc Hillman Cancer Center(Univ of Pittsburgh)

    Pittsburgh, Pennsylvania, 15232-1309

    Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota, 55905-0001

    Recruiting

  • Huntsman Cancer Institute

    Salt Lake City, Utah, 84112-5550

    Recruiting

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington, 98109-4433

    Recruiting

  • Moffitt Cancer Center

    Tampa, Florida, 33612-9496

    Recruiting

  • Texas Oncology Tyler

    Tyler, Texas, 75702-7522

    Recruiting

  • Midwestern Regional Medical Center

    Zion, Illinois, 60099-2676

    Recruiting

Other trials in United States

China20 sites, 19 recruiting

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, 100730

    Recruiting

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, 410011

    Recruiting

  • Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital

    Chengdu, Sichuan, 610071

    Recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, 630014

    Recruiting

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, 350005

    Recruiting

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, 510000

    Active, not recruiting

  • Sun Yat Sen University Cancer Center Huangpu Branch

    Guangzhou, Guangdong, 510555

    Recruiting

  • Guizhou Provincial Peoples Hospital

    Guiyang, Guizhou, 550002

    Recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicinechengzhan

    Hangzhou, Zhejiang, 310002

    Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, 150000

    Recruiting

  • Shandong Provincial Hospital

    Jinan, Shandong, 250000

    Recruiting

  • First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, 650032

    Recruiting

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, 330006

    Recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, 210029

    Recruiting

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, 530021

    Recruiting

  • Affiliated Hospital of Nantong University

    Nantong, Jiangsu, 201203

    Recruiting

  • Rui Jin Hospital Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, 200025

    Recruiting

  • Institute of Hematology and Hospital of Blood Disease

    Tianjin, Tianjin Municipality, 300020

    Recruiting

  • The Second Affiliated Hospital of Xian Jiaotong University

    Xi'an, Shaanxi, 710004

    Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, 450000

    Recruiting

Other trials in China

Australia8 sites, 8 recruiting

  • Blacktown Cancer and Haematology Centre

    Blacktown, New South Wales, NSW 2148

    Recruiting

  • Monash Health

    Clayton, Victoria, VIC 3168

    Recruiting

  • Concord Repatriation General Hospital

    Concord, New South Wales, NSW 2139

    Recruiting

  • Austin Health

    Heidelberg, Victoria, VIC 3084

    Recruiting

  • Cabrini Hospital Malvern

    Malvern, Victoria, VIC 3144

    Recruiting

  • The Alfred Hospital

    Melbourne, Victoria, VIC 3004

    Recruiting

  • Genesiscare North Shore

    St Leonards, New South Wales, NSW 2065

    Recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, QLD 4102

    Recruiting

Other trials in Australia

France7 sites, 7 recruiting

  • Centre de Lutte Contre Le Cancer Institut Bergonie

    Bordeaux, 33076

    Recruiting

  • Chu Clermont Ferrand Therapie Cellulaire and Hematolo

    ClermontFerrand, 63100

    Recruiting

  • Centre Hospitalier Le Mans

    Le Mans, 72037

    Recruiting

  • Hopital Claude Huriez Chu Lille

    Lille, 59000

    Recruiting

  • Centre Leon Berard

    Lyon, 69373

    Recruiting

  • Chu Montpellier Hopital Saint Eloi

    Montpellier, 34090

    Recruiting

  • Iuc Toulouse Oncopole

    Toulouse, 31100

    Recruiting

Other trials in France

Canada6 sites, 6 recruiting

  • Juravinski Cancer Centre

    Hamilton, Ontario, L8V 5C2

    Recruiting

  • Ciusss Nim Hscm

    Montreal, Quebec, H4J 1C5

    Recruiting

  • Jewish General Hospital

    Montreal, Quebec, QC H3t 1E2

    Recruiting

  • Chu de Quebec Universite Laval, Hopital de Lenfant Jesus, Centre Integre de Cancerologie (Cic)

    Québec, Quebec, G1J 1Z4

    Recruiting

  • Ciusss de Lestrie Chus

    Sherbrooke, Quebec, J1H 5N4

    Recruiting

  • Bc Cancer Victoria

    Victoria, British Columbia, V8R 6V5

    Recruiting

Other trials in Canada

Czechia6 sites, 6 recruiting

  • Fakultni Nemocnice Brno

    Brno, 625 00

    Recruiting

  • Fakultni Nemocnice Hradec Kralove

    Hradec Králové, 500 03

    Recruiting

  • Fakultni Nemocnice Olomouc

    Olomouc, 77900

    Recruiting

  • Fakultni Nemocnice Ostrava

    Ostrava, 708 00

    Recruiting

  • Fakultni Nemocnice Plzen

    PLZE, 323 00

    Recruiting

  • Vseobecna Fakultni Nemocnice V Praze

    Prague, 10000

    Recruiting

Other trials in Czechia

Italy6 sites, 6 recruiting

  • Irccs Azienda Ospedaliero Universitaria Bologna

    Bologna, 40138

    Recruiting

  • Aou Careggi, Servizio Sanitario Toscana

    Florence, 50134

    Recruiting

  • Ospedale San Raffaele

    Milan, 20132

    Recruiting

  • Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

    Milan, 20162

    Recruiting

  • Azienda Ospedaliera Di Padova

    Padova, 35128

    Recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli

    Roma, 00168

    Recruiting

Other trials in Italy

Brazil5 sites, 5 recruiting

  • Instituto Dor de Pesquisa E Ensino Distrito Federal

    Brasília, 70390140

    Recruiting

  • Centro Gaucho Integrado de Oncologia Hospital Mae de Deus

    Porto Alegre, 90110-270

    Recruiting

  • Ensino E Terapia de Inovacao Clinica Amo Etica

    Salvador, 41950-640

    Recruiting

  • Instituto Dor de Pesquisa E Ensino Sao Paulo

    São Paulo, 01401-004

    Recruiting

  • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein

    São Paulo, 05652-900

    Recruiting

Other trials in Brazil

New Zealand5 sites, 5 recruiting

  • North Shore Hospital

    Auckland, 0622

    Recruiting

  • Auckland City Hospital

    Auckland, 1023

    Recruiting

  • Health New Zealand Canterbury

    Christchurch, 8011

    Recruiting

  • Dunedin Hospital

    Dunedin, 9016

    Recruiting

  • Wellington Regional Hospital (Ccdhb)

    Wellington, 6021

    Recruiting

Other trials in New Zealand

Poland5 sites, 5 recruiting

  • Szpital Specjalist W Brzozowie,Podkarpacki Osrodek Onkologiczny

    Brzozów, 36-200

    Recruiting

  • Pratia Onkologia Katowice

    Katowice, 40-519

    Recruiting

  • Pratia McM Krakow

    Krakow, 30-727

    Recruiting

  • Uniwersytecki Szpital Kliniczny Nr 4 W Lublinie

    Lublin, 20-090

    Recruiting

  • Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu

    Wroclaw, 50-367

    Recruiting

Other trials in Poland

South Korea5 sites, 5 recruiting

  • The Catholic University of Korea, Seoul St Marys Hospital

    SeochoGu, Seoul Teugbyeolsi, 06591

    Recruiting

  • Severance Hospital Yonsei University Health System

    SeodaemunGu, Seoul Teugbyeolsi, 03722

    Recruiting

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, 13620

    Recruiting

  • Seoul National University Hospital

    Seoul, Seoul Teugbyeolsi, 03080

    Recruiting

  • Asan Medical Center

    SongpaGu, Seoul Teugbyeolsi, 05505

    Recruiting

Other trials in South Korea

United Kingdom5 sites, 5 recruiting

  • Queen Elizabeth Hospital

    Birmingham, B15 2TH

    Recruiting

  • University Hospitals Dorset Royal Bournemouth Hospital

    Bournemouth, BH7 7DW

    Recruiting

  • St Jamess University Hospital

    Leeds, LS9 7TF

    Recruiting

  • Kings College Hospital

    London, SE5 9RS

    Recruiting

  • Norfolk and Norwich University Hospitals Nhs Foundation Trust

    Norwich, NR4 7UY

    Recruiting

Other trials in United Kingdom

Germany4 sites, 4 recruiting

  • Donauisar Klinikum Deggendorf Klinik Fur Onkologie Und Hamatologie

    Deggendorf, 94469

    Recruiting

  • Centrum Fur Haematologie Und Onkologie Bethanien

    Frankfurt am Main, 60389

    Recruiting

  • Geho Munster

    Münster, 48153

    Recruiting

  • Klinikum St Elisabeth Straubing Gmbh Mvz Klinikum Straubing Gmbh

    Straubing, 94315

    Recruiting

Other trials in Germany

Spain4 sites, 4 recruiting

  • Hospital Universitario Virgen de Las Nieves

    Granada, 18014

    Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, 28041

    Recruiting

  • Hospital Universitario Puerta de Hierro Majadahonda

    Majadahonda, 28222

    Recruiting

  • Hospital Clinico Universitario Virgen de La Arrixaca

    Murcia, 30120

    Recruiting

Other trials in Spain

Netherlands3 sites, 3 recruiting

  • Flevoziekenhuis

    Almere Stad, 1315 RA

    Recruiting

  • Albert Schweitzer Ziekenhuis

    Dordrecht, 3318 AT

    Recruiting

  • Hagaziekenhuis

    Sgravenhage, 2545 AA

    Recruiting

Other trials in Netherlands

Romania3 sites, 3 recruiting

  • Coltea Clinical Hospital

    Bucharest, 30171

    Recruiting

  • Institutul Clinic Fundeni

    Bucureti, 022328

    Recruiting

  • Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca

    ClujNapoca, 400015

    Recruiting

Other trials in Romania

Sweden1 site, 1 recruiting

  • Karolinska Universitetssjukhuset Solna

    Stockholm, 171 76

    Recruiting

Other trials in Sweden

About this study

Official title: A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Previously Untreated Chronic Lymphocytic Leukemia

The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).

Being tested
Sonrotoclax, Zanubrutinib, Acalabrutinib, Venetoclax
Keywords
B-cell Lymphoma-2 Inhibitor, Bruton Tyrosine Kinase Inhibitor
Medical subject headings
Leukemia, Lymphocytic, Chronic, B-Cell

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SonrotoclaxDrug

    Also called BGB-11417

    Administered orally.

  • ZanubrutinibDrug

    Also called BGB-3111, Brukinsa

    Administered orally.

  • AcalabrutinibDrug

    Also called Calquence

    Administered orally.

  • VenetoclaxDrug

    Also called Venclexta, Venclyxto

    Administered orally.

Study groups in NCT07277231
Study groupRoleWhat they receive
Arm A: Sonrotoclax plus ZanubrutinibExperimentalParticipants will receive sonrotoclax and zanubrutinib for a fixed duration followed by observation.
Receives: Drug: Sonrotoclax; Drug: Zanubrutinib
Arm B: Venetoclax plus AcalabrutinibActive comparatorParticipants will receive venetoclax and acalabrutinib for a fixed duration followed by observation.
Receives: Drug: Acalabrutinib; Drug: Venetoclax

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Progression-Free Survival (PFS) as Determined by Independent Review Committee (IRC)

    PFS is defined as the time from the date of randomization to the date of disease progression as determined by IRC or death due to any cause, whichever occurs first.

    Measured: Up to approximately 70 months

  2. Rate of Undetectable Minimal Residual Disease at < 10^-4 sensitivity (uMRD4)

    Rate of uMRD4 is defined as the percentage of participants that achieved uMRD4 measured in both peripheral blood (PB) and bone marrow aspirate (BMA) at the post-treatment follow-up visit (PTFU1) based on next generation sequencing (NGS).

    Measured: Up to approximately 16 months

Secondary outcomes (11)

  1. PFS in High-Risk Participants

    PFS is defined as the time from the date of randomization to the date of disease progression as determined by IRC or death due to any cause, whichever occurs first.

    Measured: Up to approximately 70 months

  2. Overall Survival (OS)

    OS is defined as the time from the date of randomization to the date of death due to any cause.

    Measured: Up to approximately 70 months

  3. Overall Response Rate (ORR) as Determined by IRC

    ORR is defined as the percentage of participants with a complete response (CR), complete response with incomplete hematopoietic recovery (CRi), nodal partial response (nPR), or partial response (PR), before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier), as assessed by IRC.

    Measured: Up to approximately 70 months

  4. Rate of Undetectable Minimal Residual Disease at < 10^-5 sensitivity (uMRD5)

    Rate of uMRD5 is defined as the percentage of participants who achieved uMRD5 measured in both PB and BMA at the PTFU1 Visit based on NGS, before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier).

    Measured: Up to approximately 16 months

  5. Number of Participants with Adverse Events

    Number of participants with treatment-emergent adverse events (TEAEs), adverse events of clinical interest, and serious adverse events (SAEs), including laboratory values, vital signs, and physical examination findings.

    Measured: Up to approximately 70 months

  6. PFS Determined by Investigator Assessment

    PFS is defined as the time from the date of randomization to the date of disease progression as determined by investigator or death due to any cause, whichever occurs first.

    Measured: Up to approximately 70 months

  7. Complete Response Rate (CRR) by IRC and Investigator Assessment

    CRR is defined as the percentage of participants with a CR or CRi before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier).

    Measured: Up to approximately 70 months

  8. ORR Determined by Investigator Assessment

    ORR is defined as the percentage of participants with a complete response or partial response, before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier), as assessed by investigator.

    Measured: Up to approximately 70 months

  9. Duration of Response (DOR)

    Duration of response (determined by both IRC and investigator assessment) is defined as the time from the first qualifying response (CR, CRi, nPR, or PR) until CLL progression or death. DOR analysis will only include responders.

    Measured: Up to approximately 70 months

  10. Time to Next Treatment (TTNT)

    TTNT is defined as the time from randomization to the start of the next treatment for CLL.

    Measured: Up to approximately 70 months

  11. Change from Baseline in Score on European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL)-409 Questionnaire

    Patient-reported symptoms of global health status (GHS), role functioning, and physical functioning, symptom burden and physical condition/fatigue will be measured using the European Organization for Research and Treatment of Cancer quality of life questionnaire EORTC IL-409 (an itemized version of [EORTC] quality of life questionnaire core 30 [QLQ-C30] and its CLL module CLL17). The EORTC-IL-409 consists of 17 questions answered on a 4-point scale where 1 = Not at all (best) to 4 = Very Much (worst) and 2 global health questions answered on a 7-point scale where 1 = Very poor (worst) to 7 = Excellent (best). Higher scores in GHS and functional scales and lower scores in symptom scales indicate better quality of life.

    Measured: At baseline and up to approximately 70 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Dec 2025
  2. Study start22 Jan 2026
  3. Primary completionFeb 2031 (estimated)
  4. Study completionNov 2031 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07277231
Sponsor's protocol ID
BGB-11417-304
Other IDs
2025-524366-21-00, 2025
Status last verified
Sep 2026
First submitted
2 Dec 2025
Last updated
28 Sep 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Sonrotoclax, Zanubrutinib and Acalabrutinib in people with Chronic Lymphocytic Leukemia, run by BeOne Medicines at 115 sites in 17 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 28 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 115 sites in United States, China, Australia, France, Canada and 12 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Study Director (8778285568, clinicaltrials@beonemed.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Progression-Free Survival (PFS) as Determined by Independent Review Committee (IRC) (time frame: Up to approximately 70 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07277231.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in